All In Biotech

NDA 022195 · Hikma

Morphine Sulfate

Morphine Sulfate · Oral

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Mar 17, 2008

Approved uses

3

Original approval plus efficacy supplements

Registered trials

2,053

400 Phase 3, 129 recruiting

FAERS reports

67,702

52,278 serious, 12,172 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MORPHINE SULFATE ORAL SOLUTION Risk of Medication Errors Ensure accuracy when prescribing, dispensing, and administering Morphine Sulfate Oral Solution. Dosing errors due to confusion between mg and mL, and other morphine sulfate oral solutions of different concentrations can result in accidental overdose and death [see Dosage and Administration (2.1) , Warnings and Precautions (5.1) ]. Addiction, Abuse, and Misuse Because the use of Morphine Sulfate Oral Solution exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.2) ]. Life-Threatening Respiratory Depression Serious, life-threatening, or...

What it is approved for

From the label in effect Aug 26, 2026.

Morphine Sulfate Oral Solution 2 mg/mL and 4 mg/mL is indicated for the management of: adults with acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. pediatric patients 2 years of age and older with acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Morphine Sulfate Oral Solution 20 mg/mL is indicated for the relief of acute and chronic pain in opioid-tolerant adult patients. Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions (5.2) ] , reserve Morphine Sulfate Oral Solution for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. Morphine Sulfate Oral Solution should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. Morphine Sulfate Oral Solution is an opioid agonist. Morphine Sulfate 2 mg/mL and 4 mg/mL is indicated for the management of: adults with acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) pediatric patients 2 years of age and older with acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Morphine Sulfate Oral Solution 20 mg/mL is indicated for: the relief of acute and chronic pain in opioid-tolerant adult patients. ( 1 ) Limitations of Use ( 1 ):...

Mechanism: Morphine is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 2, 2021 Supplement 10 · Efficacy LetterLabel
  • Jan 25, 2010 Supplement 2 · Efficacy · priority review LabelLetter
  • Mar 17, 2008 Original approval · Type 7 - Drug Already Marketed without Approved NDA REMSLabelReview
3 products under this application
  • MORPHINE SULFATE · MORPHINE SULFATE 100MG/5ML · SOLUTION, ORAL · Prescription · TE AA
  • MORPHINE SULFATE · MORPHINE SULFATE 10MG/5ML · SOLUTION, ORAL · Prescription · TE AA
  • MORPHINE SULFATE · MORPHINE SULFATE 20MG/5ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Morphine" as an intervention, any sponsor and status, largest first.

All 2,053 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence10,516
  • drug hypersensitivity10,154
  • pain9,236
  • overdose7,799
  • emotional distress5,177
  • nausea4,695
  • dependence4,682
  • drug ineffective4,473
  • death4,265
  • fatigue3,372
  • drug withdrawal syndrome3,367
  • vomiting3,311

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,243
20051,049
2006952
2007529
2008649
2009698
2010892
20111,190
20121,838
20131,464
20141,860
20152,350
20162,902
20172,703
20185,576
20194,345
20203,840
20217,871
20228,454
20238,186
20243,559
20253,350
20262,199

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Morphine Sulfate* (Morphine Sulfate)

2024 spending

$17.1M

Beneficiaries

240,437

721,076 claims

Per beneficiary

$71

$0.39 per unit

View as table
YearSpending
2020$23,761,810
2021$20,733,114
2022$19,694,207
2023$18,551,347
2024$17,055,438

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8,877 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.